Abstract
Sudden cardiac arrest is a leading cause of death worldwide with survival rates still remaining suboptimal. Unfortunately, most cardiac arrest patients, who achieve return of spontaneous circulation (ROSC), develop a multi-faceted post-cardiac arrest syndrome, including post-cardiac arrest brain injury, myocardial dysfunction, and systemic ischemia/reperfusion response.
Erythropoietin (EPO), the principal hematopoietic hormone regulating erythropoiesis, exhibits diverse cellular effects in nonhematopoietic tissues. Due to its anti-apoptotic, anti-inflammatory, and anti-oxidant properties, as well as its angiogenic action, EPO plays a role in neuroprotection and cardioprotection. In this regard, EPO represents a promising agent in the cardiac arrest setting, based on a therapeutic strategy that focuses on the post-resuscitation phase.
This review aims to provide a comprehensive account of EPOs role in the treatment of each individual component of post-cardiac arrest syndrome.
Keywords: Erythropoietin, Cardiac arrest, Post-cardiac arrest syndrome, Neuroprotection, Cardioprotection, Anti-oxidant, hematopoietic, heterotrimer, dysfunction, reperfusion, homeostasis, cardiopulmonary, leukocytes, apoptotic, P-selectin, astrocytes, hypoxic, necrosis
Current Pharmaceutical Design
Title: The Potential Role of Erythropoietin as a Pleiotropic Agent in Post-cardiac Arrest Syndrome
Volume: 17 Issue: 15
Author(s): Theodoros Xanthos, Panagiotis V.S. Vasileiou, Sotirios Kakavas, Aggeliki Syggelou and Nicoletta Iacovidou
Affiliation:
Keywords: Erythropoietin, Cardiac arrest, Post-cardiac arrest syndrome, Neuroprotection, Cardioprotection, Anti-oxidant, hematopoietic, heterotrimer, dysfunction, reperfusion, homeostasis, cardiopulmonary, leukocytes, apoptotic, P-selectin, astrocytes, hypoxic, necrosis
Abstract: Sudden cardiac arrest is a leading cause of death worldwide with survival rates still remaining suboptimal. Unfortunately, most cardiac arrest patients, who achieve return of spontaneous circulation (ROSC), develop a multi-faceted post-cardiac arrest syndrome, including post-cardiac arrest brain injury, myocardial dysfunction, and systemic ischemia/reperfusion response.
Erythropoietin (EPO), the principal hematopoietic hormone regulating erythropoiesis, exhibits diverse cellular effects in nonhematopoietic tissues. Due to its anti-apoptotic, anti-inflammatory, and anti-oxidant properties, as well as its angiogenic action, EPO plays a role in neuroprotection and cardioprotection. In this regard, EPO represents a promising agent in the cardiac arrest setting, based on a therapeutic strategy that focuses on the post-resuscitation phase.
This review aims to provide a comprehensive account of EPOs role in the treatment of each individual component of post-cardiac arrest syndrome.
Export Options
About this article
Cite this article as:
Xanthos Theodoros, V.S. Vasileiou Panagiotis, Kakavas Sotirios, Syggelou Aggeliki and Iacovidou Nicoletta, The Potential Role of Erythropoietin as a Pleiotropic Agent in Post-cardiac Arrest Syndrome, Current Pharmaceutical Design 2011; 17 (15) . https://dx.doi.org/10.2174/138161211796197115
DOI https://dx.doi.org/10.2174/138161211796197115 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
One-Compound-Multi-Target: Combination Prospect of Natural Compounds with Thrombolytic Therapy in Acute Ischemic Stroke
Current Neuropharmacology Pharmacology of L-type Calcium Channels: Novel Drugs for Old Targets?
Current Molecular Pharmacology Brain Injury Associated with Widely Abused Amphetamines: Neuroinflammation, Neurogenesis and Blood-Brain Barrier
Current Drug Abuse Reviews From Bone to Brain: Human Skeletal Stem Cell Therapy for Stroke
Central Nervous System Agents in Medicinal Chemistry Minocycline Repurposing in Critical Illness: Focus on Stroke
Current Topics in Medicinal Chemistry Therapeutic Hypothermia and Neuroprotection in Acute Neurological Disease
Current Medicinal Chemistry Regenerative Potential of Stem Cell-derived Extracellular Vesicles in Spinal Cord Injury (SCI)
Current Stem Cell Research & Therapy Immune-Neuroendocrine Interactions Involving Thymus and Pineal Gland in Stem Cell Therapy of Age-Related Diseases
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Endogenous and Exogenous CNS Derived Stem / Progenitor Cell Approaches for Neurotrauma
Current Drug Targets Treatment for Radiation-Induced Pulmonary Late Effects: Spoiled for Choice or Looking in the Wrong Direction?
Current Drug Targets Genus Salacia: Chemical Composition, Antidiabetic Effect and other Bioactivities
The Natural Products Journal Targeting the Cholinergic System for Neuroprotection and/or Enhancement of Functional Recovery Following Neurotrauma
Current Pharmaceutical Design Recent Advances in the Comprehension and the Management of Perioperative Systemic Host Response During Cardiopulmonary Bypass
Recent Patents on Cardiovascular Drug Discovery The Clinical Neuroscience of Post Stroke Depression
Current Neuropharmacology Antibody Mediated Rejection in Pig-To-Nonhuman Primate Xenotransplantation Models
Current Drug Targets - Cardiovascular & Hematological Disorders Cannabinoids, Immune System and Cytokine Network
Current Pharmaceutical Design NMDA/NR2B Selective Antagonists in the Treatment of Ischemic Brain Injury
Current Drug Targets - CNS & Neurological Disorders Not Just the Brain: Methamphetamine Disrupts Blood-Spinal Cord Barrier and Induces Acute Glial Activation and Structural Damage of Spinal Cord Cells
CNS & Neurological Disorders - Drug Targets The Association of Microglial Activation and Amyloid Reduction in APP+PS1 Transgenic Mice
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Transgenic Overproduction of Omega-3 Polyunsaturated Fatty Acids Provides Neuroprotection and Enhances Endogenous Neurogenesis After Stroke
Current Molecular Medicine